{"id":"NCT00092456","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Consistency Lots Vaccine Study (V260-009)","officialTitle":"Comparison of the Immunogenicity and Safety of Three Consistency Lots of V260 in Healthy Infants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2003-05","primaryCompletion":"2004-08","completion":"2004-08","firstPosted":"2004-09-27","resultsPosted":"2011-04-12","lastUpdate":"2015-10-05"},"enrollment":793,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Rotavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"rotavirus vaccine, live, oral, pentavalent","otherNames":["V260","RotaTeq™"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"RotaTeq™ Lot 1","type":"EXPERIMENTAL"},{"label":"RotaTeq™ Lot 2","type":"EXPERIMENTAL"},{"label":"RotaTeq™ Lot 3","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study was designed to evaluate consistency in the antibody response to three manufactured lots of an investigational Rotavirus Vaccine.","primaryOutcome":{"measure":"Serum Neutralizing Antibodies (SNA) Response Against Rotavirus Serotypes G1, G2, G3, G4 and P1A[8]","timeFrame":"42 days following the 3rd vaccination","effectByArm":[{"arm":"RotaTeq™ Lot 1","deltaMin":167.9,"sd":null},{"arm":"RotaTeq™ Lot 2","deltaMin":193.2,"sd":null},{"arm":"RotaTeq™ Lot 3","deltaMin":171,"sd":null},{"arm":"Placebo","deltaMin":9.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":1,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":226},"commonTop":["Pyrexia","Diarrhoea","Vomiting","Upper respiratory tract infection","Otitis media"]}}